For more than 30 years, at Asofarma, we have consolidated a broad portfolio to offer physicians and patients in Central America and the Caribbean innovative and high-quality therapeutic solutions, with the aim of improving the quality of life of the country´s population. We cover multiple therapeutic areas in order to offer the best possible therapies.
Cardiovascular diseases are the main cause of death in the world and in most of the American countries. Asofarma offers a wide portfolio for the treatment of hypertension, hypercholesterolemia and anticoagulation.
Diabetes has become one of the main causes of death and disability in the region of America. We have products for the treatment of Type I and Type II Diabetes.
Pain management aims to improve the quality of life of patients with pain by reducing their suffering. Leading molecules in the treatment of pain, both for acute and chronic pain, are part of our portfolio.
Rare Diseases (RD) as an emerging concept, is used to define those diseases of low prevalence, high severity and debilitating chronic course. These diseases affect multiple systems and organs.
Gastroenterological diseases are those that attack the stomach and intestines. They can be caused by bacteria, parasites, viruses and some foods, although there are also some medications that cause them. Both for the treatment of peptic ulcer disease and irritable bowel syndrome, we have effective molecules.
Gynecology is a specialty of medicine that focuses on the study of the female reproductive system. Women´s health care is one of the objectives covered with our products. We have a wide arsenal of both, oral and device contraceptives.
They are those diseases of the blood and related organs such as bone marrow, lymph nodes and spleen, the main pathologies being anemia, thrombopathy, lymphomas, hemophilia and leukemia. We represent biotech companies that develop innovative molecules to treat these diseases.
Immune diseases generate an inadequate functioning of the immune system, which is responsible for defending us against infections. Among the most common immune diseases are rheumatoid arthritis, multiple sclerosis and myasthenia gravis. Our portfolio includes drugs with target molecules in the treatment of these pathologies.
Neurological disorders are diseases of the central and peripheral nervous systems. Both to treat patients with Alzheimer´s disease, as well as Epilepsies and Parkinson, we have the most modern and effective molecules.
Obesity is a complex disease that consists of having an excessive amount of body fat. Obesity is not just an aesthetic problem. In the obesity treatment, we provide different molecules and combinations that contribute to achieving the stated objective.
Oncological diseases are the second cause of death in industrialized countries. However, periodical medical control and early diagnosis of these diseases greatly reduce their severity. We have a wide portfolio of drugs aimed at fighting different types of cancer that can affect the lung, breast, pancreas or bile ducts.
In this group of diseases, all the pathologies that involve the deterioration and dysfunction of the bone and joint system are grouped. For degenerative joint disease, we have successful combinations, as well as devices for viscosupplementation.
Osteoporosis has been considered the main cause of morbidity in older adults due to disability and hospitalizations. For the treatment of osteoporosis and osteopenia, we offer an innovative portfolio, both in prevention, as well as improvement and reduction of fracture risks.
Psychiatric disorders are illnesses that manifest primarily as disorders of thought, emotion, or behavior, and that cause discomfort or functional impairment. We have multiple therapeutic alternatives for the treatment of many psychiatric ailments.
Urological diseases are those that affect the urinary system causing disorders and infections in the urinary system as well as in the bladder. For the treatment of overactive bladder, benign prostatic hyperplasia, as well as for erectile dysfunction, our portfolio has the most innovative drugs in the specialty.